Gilead Earlier Announced Phase 2 Evoke-02 Study Of Trodelvy (Sacituzumab Govitecan-hziy) In Combination With Keytruda (Pembrolizumab) Demonstrates Clinical Activity In First-line Metastatic Non-small Cell Lung Cancer
Portfolio Pulse from Charles Gross
Gilead Sciences announced early data from the Phase 2 EVOKE-02 study evaluating Trodelvy in combination with Merck’s KEYTRUDA in patients with previously untreated advanced or metastatic non-small cell lung cancer. The results show encouraging activity of Trodelvy in combination with KEYTRUDA across all PD-L1 subgroups and histologies studied, supporting further investigation.
September 10, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead's Phase 2 EVOKE-02 study shows promising results for Trodelvy in combination with Merck’s KEYTRUDA in treating non-small cell lung cancer.
The promising results from the Phase 2 EVOKE-02 study of Trodelvy, a drug developed by Gilead, in combination with Merck’s KEYTRUDA, could potentially lead to increased sales and revenue for Gilead if the drug is approved for use. This could have a positive impact on Gilead's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100